Genmab Strengthens Oncology Portfolio With $1.8 Billion Acquisition of ProfoundBio
By Dominic Chopping
Danish biotechnology company Genmab will acquire U.S. ProfoundBio for $1.8 billion in cash as it looks to bolster its pipeline of cancer treatments.
The acquisition will give Genmab worldwide rights to a portfolio of next-generation antibody-drug conjugates, or ADCs, which are manufactured antibodies that are administered to patients intravenously designed to deliver drugs to tumors.
This developing technology allows only the cancer cells to be targeted, unlike traditional chemotherapy treatments that can damage healthy cells and come with a number of side effects.
ProfoundBio currently has three candidates in clinical development and multiple preclinical programs, including Rina-S, which is being developed to treat ovarian cancer and other solid tumors.
Earlier this year, the U.S. Food and Drug Administration granted fast track designation to Rina-S for the treatment of patients with certain types of ovarian cancer.
"The combination of ProfoundBio's novel ADC technology platforms with Genmab's proprietary antibody platforms will potentially create new opportunities to generate and develop new medicines with the potential to transform the treatment of cancer and improve the lives of patients," Genmab said in a statement.
The proposed transaction, which has been unanimously approved by the boards of both companies, is expected to close in the first half of 2024, subject to conditions.
ProfoundBio is headquartered in Seattle, Washington and has a research and development center in Suzhou, China.
Write to Dominic Chopping at dominic.chopping@wsj.com
Corrections & Amplifications
This item was corrected at 8:50 a.m. ET to show that ADCs are manufactured antibodies that are administered to patients intravenously designed to deliver drugs to tumors. An earlier version incorrectly said ADCs are designed to use the body's own antibodies to deliver drugs to tumors.
(END) Dow Jones Newswires
April 03, 2024 04:08 ET (08:08 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
5 Stocks to Buy While They’re Trading at Big Discounts
-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
After Earnings, Is Uber Stock a Buy, a Sell, or Fairly Valued?
-
Lowe’s Earnings: Tumultuous Macro Weighs on Near-Term Results but Fails to Sway Our Long-Term View
-
Macy’s Earnings: Plan Taking Shape Despite Tough Environment
-
JPMorgan Investor Day: CEO Dimon Pushes Against More Stock Buybacks at Current Prices
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?